回复：迷迷糊糊的疱疹系列研究----先从感叹开始
订正一下， 第二个疫苗是目前在英国正在进行临床试验的疫苗， 已进入临床一期试验， 试验结果也是非常positive （正面） 有42个志愿者参加试验了， 结果良好， 目前已经进入第二年， 去年开始的， 即将进入二期
而且这个疫苗虽主要针对没有患病者， 但对已经得了的我们也有防止复发和传播的作用， 所以订正下第二种对我们也是间接有用！
The Phase 1 study is an open label ascending dose trial, assessing safety and immune response in healthy volunteers. The study is taking place in the UK at the Chelsea and Westminster Hospital in London and will involve up to 42 already identified subjects.
ImmunoVEXHSV2 is based on a proprietary engineered form of the causative agent of genital herpes, HSV-2, from which genes that collectively interfere with the functions of immune system have been deleted. The proteins encoded by these genes aid wild type HSV-2 in evading the body’s immune system.
ImmunoVEXHSV2 expresses all but four of the approximately 80 HSV-2 proteins, maximizing the breadth of the anti-HSV immune response generated, but without the genes encoding for these immune-inhibiting proteins.
ImmunoVEXHSV2 has been evaluated in the industry-standard preclinical model of genital herpes, in which it completely prevented disease, suggesting that ImmunoVEXHSV2 may be more potent in humans than other HSV-2 vaccines for which published data is available. The vaccine also considerably reduced the level of viral shedding following exposure, which if this translates to the clinical setting, may also reduce any window of infectivity from an infected individual.
